ClinicalTrials.gg
RecruitingNCT05482854Updated Sep 29, 2023

Assessment of HIV Remission Upon cART Interruption in Early Treated Individuals Carrying the MHC B35/53Bw4TTC2 Genotype

An interventional study of Analytical Treatment Interruption (ATI) in HIV Infections, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 30 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by ANRS, Emerging Infectious Diseases · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases — 12 open to participants now, 13 under way, none of them phase 3. HIV Infections · ANRS, Emerging Infectious Diseases.

Planned enrollment
42nd of 50
50 · median 207
Started
2023
with 2 others
No phase
24 of 73
4 open now
Primary completion
2024-12
later than 1 of 12 live
Registered
60th of 73
by date

Among the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, this one is the 42nd largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2023, is one of 24 with no phase, reaches primary completion later than 1 of the 12 other live ones, and was the 60th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

12 of the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, or all of them as a file.
02

Study summary

The aim of the trial is to evaluate in ANRS CO6 PRIMO cohort participants if the presence of the MHC B35 (53) Bw4TTC2 genotype favors the control of HIV infection (defined by a viral load (VL) less than 400 cp/mL) after discontinuation of antiretroviral therapy (ART) initiated during primary HIV infection.

The trial will be a pilot "proof of concept", one arm, multicenter, nested in the ANRS CO6 PRIMO Cohort, in which the intervention is treatment interruption (of at least 6 months).

It is planned to include between 20 and 50 participants.

Read the detailed description

The ANRS 175 RHIVIERA 01 trial will focus on people who were initiated early and have a particular genotypic profile associated with HIV remission.

The study proposes to test an intervention consisting in a ART-treatment interruption (of at least 6 months) in ANRS CO6 PRIMO cohort participants carrying the MHC B35/53Bw4TTC2 genotype and well controlled on cART.

The study aims to enrol 20-30 participants in 30 French clinical sites. Participants will be enrolled after checking eligibility criteria and will interrupt ART immediatly after inclusion.

Control of HIV-Infection, defined by a viral load less than 400 cp/mL, will be evaluated after 24 weeks of interruption.

Study duration will vary by participant, depending on the time of ART interruption and the time to viral rebound. Participants will be followed maximum 48 weeks on ATI. If there is a viral rebound justifying the resumption of ART, participant will be followed 24 weeks maximum after resumption. The maximum duration of the study will be 48+24 = 72 weeks.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • treatment interruption
  • HIV remission
  • Post-treatment control
  • HLA-B35
  • Early treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years at the time of consent
  • Enrolled and currently followed in a site of the ANRS CO6 PRIMO Cohort
  • With the MHC genotype: at least one HLA B35 or B53 allele AND one HLA-A or B allele carrying the Bw4 epitope AND homozygous -21T residue in the HLA-B alleles AND heterozygous or homozygous for C2 epitope-carrying HLA-C alleles
  • Treated with cART within 3 months following inclusion in ANRS CO6 Primo Cohort during at least 18 months and cART not modified in the last 3 months
  • Controlled on cART: > 90% of VL below 50 cp/mL after initial virological response
  • All VL below 50 cp/mL during the previous 12 months
  • Most recent CD4 measurement on cART above 500 cells/mm3
  • Written and signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the study (article L1122-1-1 of the Public Health Code)
  • Person affiliated or beneficiary of a social security scheme (article L1121-11 of the Public Health Code) (State Medical Aid or AME is not a social security scheme)
  • Patient agreeing to participate in the trial according to the defined procedures.

Exclusion criteria

Exclusion Criteria:

  • One VL above 1000 cp/mL on or off antitretrovirals after the initial viral control on antiretrovirals was achieved.
  • Patient on long-acting injectable treatment
  • Patient in whom condom sex use or PrEP use by the partner will be difficult or impossible.
  • Woman with a pregnancy project and pregnant woman.
  • Patient under guardianship or curatorship.
  • History of a clinical AIDS event or cancer.
  • Active or infection.
  • Any symptoms or laboratory values suggesting a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or other medical conditions, related to HIV or not, which contraindicates the interruption of ARVs.
  • Recent SARS-CoV-2 infection and / or associated with a drop in CD4 and / or associated with a resumption of CV in the last 6 months. In this situation, wait until the CD4 has returned to a rate > 500/mm3 and a CV \< 50 copies / mL consolidated for > 6 months.
  • Affection, disability, resulting from a SARS-CoV-2 infection, regardless of the duration of the SARS-CoV-2 infection.
  • Patient participating in another research evaluating other treatments with an exclusion period ongoing at the screening visit.
  • Planned absence which could prevent optimal trial participation (vacation abroad, moving, imminent job change ...).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Patients treated early and carrying the MHC B35/53Bw4TTC2 Genotype

    Patients included in the ANRS CO6 PRIMO cohort, treated early and carrying the MHC B35/53Bw4TTC2 Genotype

    Other: Analytical Treatment Interruption (ATI)

Interventions

  • OtherAnalytical Treatment Interruption (ATI)

    Analytical Interruption of Treatment for 24-48 weeks ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a Plasma HIV-1 RNA (viral load,VL) below 400 copies/mL at 6 months after Treatment interruption (Week 24).

    Proportion of subjects with a Plasma HIV-1 RNA below 400 copies/mL on subjects included at 6 months after Treatment interruption.

    Time frame: Six months after treatment interruption (Week 24).

Secondary outcomes

  1. The acceptation rate of the trial by eligible patients

    Percentage of patients who accept to participate on patients pré-screened and eligible

    Time frame: At inclusion (Day 0)

  2. Proportion of patients with a plasma VL < 50 copies/ml at 3 and 6 months following Analytic Treatment Interruption (ATI)

    Proportion of patients with a plasma VL \< 50 copies/ml at 3 and 6 months following ATI

    Time frame: At 3 months (week 12) and 6 months (week 24) following ATI

  3. Evolution of number of CD4 T cells count during ATI and after ART resumption

    Measurement of CD4 T cells count at Screening, Day 0, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 36, Week 48, Day 0 ART resumption, Week 4 resumption, Week 12 resumption, Week 24 resumption

    Time frame: During all ATI period (from Day 0 to Day 0 ART resumption - maximum 48 weeks) and during ART resumption period (maximum 24 Weeks)

  4. Evolution of CD4 to CD8 ratio during ATI and after ART resumption

    Measurement of CD4 to CD8 at Screening, Day 0, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 36, Week 48, Day 0 ART resumption, Week 4 resumption, Week 12 resumption, Week 24 resumption

    Time frame: During all ATI period (from Day 0 to Day 0 ART resumption - maximum 48 weeks) and during ART resumption period (maximum 24 Weeks)

  5. Evolution of total and integrated HIV DNA and cell-associated HIV RNA transcripts

    Quantification of total HIV-DNA and integrated HIV-DNA by ultrasensitive techniques (ultrasensitive real-time PCR and Alu PCR) Quantification of intracellular HIV-RNA transcripts by ultrasensitive technique (ultrasensitive qPCR gag).

    Time frame: During ATI period (At Day 0, Week 4, Week 12, Week 24) and during ART resumption period (at Day 0 Resumption, and Week 24 ART Resumption)

  6. Evolution of HIV markers in sperm (on 25 participants)

    Quantification of HIV DNA on semen cells (ultrasensitive technique) and quantification of HIV RNA on seminal fluid (ultrasensitive technique)

    Time frame: During ATI period (At Day 0, Week 4, Week 12, Week 24) and at Day 0 ART resumption

  7. Evolution of the levels of inflammation markers during ATI

    Physiological parameters levels will be studied (Luminex and Simoa technology): IFNα, TGFβ, IL-7, IL-12, IL-15, IL-18, IP-10, DPPIV, ARNr 16S, I-FABP, citrulline, sCD14, sCD163

    Time frame: During ATI period (up to week 24 ATI) and at Day 0 ART resumption

  8. Proportion of patients who resumed treatment during the first 6 months of ATI, according to the reasons for resuming

    Percentage of resumption, according to the reasons listed in the protocol, before the evaluation of the primary outcome

    Time frame: At week 24

  9. Pharmacological dosages of antiretrovirals performed during the ATI from frozen samples

    Pharmacological dosages of antiretrovirals performed during the ATI at Week 2 and Week 24 of ATI

    Time frame: At Week 2 and Week 24 of ATI

  10. Proportion of patients reporting at each visit to use condoms

    Document the emphasis being placed on the impact of access to information on prevention behaviors and the quality of sexual life.

    Time frame: From date of inclusion to the last follow-up visit, up to 72 weeks (average of 1 year).

  11. Proportion of patients reporting at each visit to have proposed PrEP at their partners

    Document the emphasis being placed on the impact of access to information on prevention behaviors and the quality of sexual life.

    Time frame: From date of inclusion to the last follow-up visit, up to 72 weeks (average of 1 year).

  12. Proportion of patients satisfied with their participation at the end of the trial

    Through statistical analyses of some self-administered questionnaires items (Likert). On a Likert scale, a person selects one option among several that reflects how much they agree with a statement. The scale generally consists of five or seven balanced responses that people can choose from.

    Time frame: Questionnaire at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate)

  13. Evolution of the level of the quality of life between inclusion and the end of the trial

    Through statistical analyses of some self-administered questionnaires items ( SF12.v2 scale for quality of life). The 12-item Short-Form Health Survey is a widely used, generic patient-reported measure of health status that provides summary scores of physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: Questionnaire at Day 0, at Week 24 (or resumption of ART) and at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate)

  14. Evolution of the global satisfaction with sexual life between inclusion and the end of the trial

    Through statistical analyses of some self-administered questionnaires items (Likert). On a Likert scale, a person selects one option among several that reflects how much they agree with a statement. The scale generally consists of five or seven balanced responses that people can choose from.

    Time frame: Questionnaire at Day 0, at Week 24 (or resumption of ART) and at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate)

07

Study locations

9 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2024, 21 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 21 months is below that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2022
First posted
Aug 1, 2022
StartActual
Mar 20, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Jul 2025
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05482854
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Mar 20, 2023
Primary completion
Dec 2024 (estimated)
Completion
Jul 2025 (estimated)
Last update
Sep 29, 2023

Study contacts

Vincent MEIFFREDY
Contact
vincent.meiffredy@inserm.fr
00 33 1 45 59 52 06
Nicolas LETURQUE
Contact
nicolas.leturque@inserm.fr
00 33 1 45 59 51 93
Cécile GOUJARD
principal investigator · Hôpital Bicêtre, Service de médecine interne et d'immunologie clinique

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion